Pharsight

Drugs that contain Alogliptin Benzoate; Metformin Hydrochloride

1. Kazano patents expiration

Can you believe KAZANO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8288539 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Jun, 2025

(1 year, 8 days from now)

US7807689 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Jun, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6172090 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(7 years ago)

US6150383 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(7 years ago)

US6329404 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(7 years ago)

US6166042 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(7 years ago)

US5965584 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(7 years ago)

US6166043 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(7 years ago)

US6150384 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(7 years ago)

US6211205 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(7 years ago)

US6303640 TAKEDA PHARMS USA Pharmaceutical composition
Aug, 2016

(7 years ago)

US6303661 TAKEDA PHARMS USA Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals
Apr, 2017

(7 years ago)

US6890898 TAKEDA PHARMS USA Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US7459428 TAKEDA PHARMS USA Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US7078381 TAKEDA PHARMS USA Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US8173663 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Mar, 2025

(8 months from now)

US8900638 TAKEDA PHARMS USA Solid preparation comprising alogliptin and metformin hydrochloride
May, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-300) Jul 27, 2026
M(M-177) Apr 05, 2019
New Combination(NC) Jan 25, 2016
New Chemical Entity Exclusivity(NCE) Jan 25, 2018

NCE-1 date: 25 January, 2017

Market Authorisation Date: 25 January, 2013

Treatment: Methods of reducing the side effects of active components administered to a diabetic patient comprising administering an insulin sensitivity enhancer such as pioglitazone in combination with a biguani...

Dosage: TABLET;ORAL

How can I launch a generic of KAZANO before it's drug patent expiration?
More Information on Dosage

KAZANO family patents

Family Patents